World News: 12:00 GMT Tuesday 28th May 2019. [Valeritas, Inc. via Globe Newswire via SPi World News]
BRIDGEWATER, N.J., May 28, 2019 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical technology company and maker of , today announced the inclusion by the American Diabetes Association (ADA) of the use of a “disposable patch-like device” for insulin delivery in the new Diabetes Technology chapter of ADA’s annual Standards of Medical Care in Diabetes for 2019, published in . The inclusion in this year’s Standards of Care marks the first time such a device has been incorporated in ADA’s current clinical practice recommendations.
“It is good news for patients and medical professionals that the ADA now includes disposable, patch-like devices in its annual Standards of Medical Care,” said John Timberlake, President and Chief Executive Officer of Valeritas. “Having a well respected organization like the ADA recognize the value of a disposable, patch-like device, such as V-Go, is significant.”
Clinical studies have consistently demonstrated that patients with type 2 diabetes who have switched from insulin injection therapy to the simple-to-use, wearable V-Go significantly lowered blood glucose with less insulin.
Studies have also demonstrated that use of V-Go for insulin therapy proved to be a more cost-effective delivery option compared to multiple daily injections using syringes or pens. Standards of Care is an official ADA position, is authored by the ADA, and provides all of the ADA’s current clinical practice recommendations. To update the Standards of Care, the ADA’s Professional Practice Committee (PPC) performs an extensive clinical diabetes literature search, supplemented with input from ADA staff and the medical community at large. is a journal produced by the American Diabetes Association, which is intended to increase knowledge, stimulate research, and promote better management of people with diabetes. Once a year, the ADA devotes an edition of its journal to provide clinicians, patients, researchers, payers, and other interested individuals with the components of diabetes care, general treatment goals, and tools to evaluate the quality of care.
Valeritas is a commercial-stage medical technology company focused on improving health and simplifying life for people with diabetes by developing and commercializing innovative technologies. Valeritas’ flagship product, , is a simple, affordable, all-in-one basal-bolus insulin delivery option for patients with type 2 diabetes that is worn like a patch and can eliminate the need for taking multiple daily shots. V-Go administers a continuous preset basal rate of insulin over 24 hours, and it provides discreet on-demand bolus dosing at mealtimes. It is the only basal-bolus insulin delivery device on the market today specifically designed keeping in mind the needs of type 2 diabetes patients. Headquartered in Bridgewater, New Jersey, Valeritas operates its R&D functions in Marlborough, Massachusetts.
More information is available at and our Twitter feed @Valeritas_US, .
This press release may contain forward-looking statements. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, references to Valeritas technologies, business and product development plans and market information. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to raise the additional funding needed to continue to pursue Valeritas’ business and product development plans, Valeritas' expected cash burn rate and its ability to continue to increase new and total prescription growth, the effects of the reverse stock split on the trading price of Valeritas’ common stock, in both the short and long-term; the inherent uncertainties associated with developing new products or technologies, the ability to continue to commercialize the V-Go® Wearable Insulin Delivery device with limited resources, competition in the industry in which Valeritas operates and overall market conditions. Statements or claims made by third parties regarding the efficacy or functionality of V-Go as compared to other products are statements made by such individual and should not be taken as evidence of clinical trial results supporting such statements or claims. Any forward-looking statements are made as of the date of this press release, and Valeritas assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents Valeritas files with the SEC available at .
Globe Newswire: 12:00 GMT Tuesday 28th May 2019
SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.